I should add that just relates to p140 in lupus, and they retain 100% of the rights to rest of world. Of course, this time they are also looking to run p140 in CIDP, another blockbuster indication at late stage where the fda has looked on the trial favourably. It is a good thing that they have ownership of late stage assets like this - some are funded, some not (yet). |
I know that of course, but nobody seems to know why Avion are taking so long. Are they still really interested? The field is progressing rapidly and they're losing time, money and momentum.
TM will surely take insurance if he can get it. |
"wiggy - they're spending so little because they're not running trials." They won't be spending much on trials, because they have already partnered with Avion in the US who will be funding the US trial. |
Good close. Rarely do spikes close so high |
I'm glad Alexander called out 2reincarnated. He pops in to disrupt Sareum conversation on lse and I'm sure he has another pseudonym on advfn.
I can't help but see a number of promising small UK bios have had such disruptors just spread negativity.
Almost as if it's orchestrated...
A cracking day here today.
I have a feeling that a reset is due for many smaller bios that have been through the rinser.
All best |
Nobby - I hope you'll never say another bad word about McCarthy! The man's a miracle-worker - talk about water into wine :¬)
I doubt he'll be able to resist raising something at this price - the only thing I think that might stop it is if he's got another bit of 'news' to release, which I could well imagine he might have.
wiggy - they're spending so little because they're not running trials. Which means that in real terms they're going backwards. Anything they might have discovered in this latest bit of froggy foraging would have to be built into the trial protocol, with all that that entails. Mr M definitely will take money if he gets half a sniff of a chance. |
At what price are the bears wrong anyway? Its all id like to know |
To repeat : "Sphere25 - one of the interesting things that might give this legs is the very low cash burn. A few posters here mention cash raise, but IMM are currently using only around £1.3m pa. If you don't use a lot of cash, then you don't need a lot of cash. This is testament to decent management really. Also, if they can get even a modest upfront from a forthcoming partnership deal then they may not need to raise at all prior to getting the trial going. ATB" |
Holding here -
Lets see the news over the course of the next few days - |
Cant find the earlier one where we started on it. If i find il post it |
Lol. Had the yanks in weeks ago |
Might stall at 6p-ish for a while (natural technical target), but when the upside is 50p+ who cares?
Don't forget, unlike Putinaire, I saw this move weeks ago (not this morning like some). |
Meaning, there is no get out clause for the follow up, in this one |
Read it carefully. the words are open to actual accountability on a follow up. They did not grey the interaction
It's strong data |
Nobby is right on the info -
However, the enticement is the holy grail breakthrough -
with very little material apart from the RNS - |
Beautiful 3-4. Maker sorted. Boys sorted. Close good |
Will get very interesting now |
Oh nobby, nobby, nobby.
Your ability to miss out on what has been right under your nose never ceases to amuse. |
? Its about to fly |
Quite significant if they say what they have -
The risk is information on the data in minimal - |
Mindflair plc (AIM: MFAI), the company investing in next generation technology focused on AI, is pleased to note the public announcement by Infinite Reality ("iR") on 8 January 2025. Key information in this announcement includes:· iR has raised additional equity of US$3 billion in cash, increasing iR's indicative valuation to US$12.25 billion.· Execution of a 5 year deal with Google Cloud.· Launch of FIM SGP-Verse in collaboration with Warner Bros Discovery Sports. |
Suspect so soul. Wont be offered to us anyway for sure |
With these results they will have some sort of funding from a big company, |
No public allowed to subscribe. |
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Hot Features
Premium
